Intelligence
Pricing

Healthcare

Protagenic Therapeutics' PT00114 Shows Promise in Treating Chronic Stress in Rodent Models

Author:
FAQSIR News Desk
Last Updated:
Reading Time
2 min

#Study Findings on PT00114

Protagenic Therapeutics, Inc., a clinical-stage biopharmaceutical company, recently announced significant findings from its preclinical trial of PT00114, aimed at treating chronic stress disorders. The results were published in the peer-reviewed journal Behavioural Pharmacology, indicating that PT00114 effectively reduced both physiological and behavioral markers of chronic stress in a rodent model.

#Efficacy in Rodent Models

In a study involving male Sprague Dawley rats subjected to a chronic unpredictable stress paradigm, PT00114 treatment led to a notable 56.4% reduction in plasma corticosterone levels compared to saline-treated control groups. This reduction in a stress hormone is significant as it correlates with enhanced resilience to chronic stress.

Furthermore, rats receiving PT00114 spent 282% more time in the center of an open field, an indicator of reduced anxiety-like behavior. Notably, this increase was not linked to changes in general locomotion, suggesting that the compound specifically alleviated anxiety rather than simply increasing activity levels.

#Comparison with Traditional Antagonists

Contrastingly, CP-154,526, a known corticotropin-releasing factor receptor 1 (CRF₁) antagonist, did not demonstrate effectiveness in the same model, even with continuous administration during the stress exposure phase. This divergence raises important questions about the mechanisms of action of different compounds in chronic stress models.

#Future Clinical Development

Given these promising preclinical results and prior positive safety outcomes from Phase 1 studies, Protagenic Therapeutics plans to advance PT00114 to further clinical trials, possibly starting in 2027. The compound is being positioned as a first-in-class investigational therapy targeting the TCAP pathway to treat stress-related neuropsychiatric conditions, including anxiety, PTSD, and treatment-resistant depression.

#Mechanism of Action

PT00114 operates through a unique mechanism, acting upstream of the CRF signaling pathway rather than directly competing with CRF at the receptor level. This could potentially offer advantages in sustaining therapeutic effects in chronic conditions, a phenomenon often compromised by other CRF₁ antagonists.

#Key Takeaways

  • PT00114 significantly reduced chronic stress markers and anxiety-like behaviors in rodent models.
  • The compound operates through a unique mechanism, differing from traditional CRF₁ antagonists.
  • Protagenic plans to initiate further clinical studies for PT00114 in 2027.
  • The findings support the potential of PT00114 in treating various stress-related neuropsychiatric disorders.
  • Results were published in Behavioural Pharmacology, validating the research's credibility.

Original source: Read original article

Frequently Asked Questions

The recent study published in Behavioural Pharmacology demonstrated that PT00114 significantly reduced both plasma corticosterone levels and anxiety-like behaviours in a rodent model of chronic stress. This suggests a potential therapeutic benefit for PT00114 in treating stress-related disorders.
Unlike traditional CRF₁ antagonists, which failed to show efficacy in chronic stress models, PT00114 maintained its effectiveness, indicating it may offer a novel mechanistic advantage for treating stress-related conditions.
PT00114 targets the TCAP pathway, potentially acting upstream of the CRF signalling cascade, which may make it less vulnerable to the compensatory adaptations often seen with CRF₁ antagonists, enhancing its therapeutic potential.
Protagenic Therapeutics plans to initiate further clinical studies for PT00114 in 2027, following positive safety results from Phase 1 studies, positioning it for potential advancements into more extensive clinical trials.
PT00114 is being developed for a range of stress-related neuropsychiatric disorders, including anxiety, PTSD, and treatment-resistant depression, reflecting a promising avenue for addressing unmet medical needs in these areas.
In the study, PT00114 was administered to male Sprague Dawley rats in a chronic unpredictable stress model, demonstrating a notable reduction in stress markers, which underscores its potential efficacy in chronic stress scenarios.
The publication in a peer-reviewed journal lends credibility to the research and findings, potentially attracting interest from investors and the wider scientific community, as it highlights the innovative approach of Protagenic Therapeutics in tackling chronic stress.
The encouraging preclinical data, coupled with positive safety outcomes from initial studies, supports a bullish outlook for PT00114's future development, indicating a strong foundation for advancing into clinical trials.